Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

Olivia Pagani, Shari Gelber, Edda Simoncini, Monica Castiglione-Gertsch, Karen N. Price, Richard D. Gelber, Stig B. Holmberg, Diana Crivellari, John Collins, Jurij Lindtner, Beat Thürlimann, Martin F. Fey, Elizabeth Murray, John F. Forbes, Alan S. Coates, Aron Goldhirsch

Research output: Contribution to journalArticle

Abstract

To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrineresponsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves diseasefree survival for postmenopausal women with endocrineresponsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high.

Original languageEnglish
Pages (from-to)491-500
Number of pages10
JournalBreast Cancer Research and Treatment
Volume116
Issue number3
DOIs
Publication statusPublished - Aug 2009

    Fingerprint

Keywords

  • Breast cancer
  • Chemoendocrine therapy
  • Estrogen receptors
  • Postmenopausal

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pagani, O., Gelber, S., Simoncini, E., Castiglione-Gertsch, M., Price, K. N., Gelber, R. D., Holmberg, S. B., Crivellari, D., Collins, J., Lindtner, J., Thürlimann, B., Fey, M. F., Murray, E., Forbes, J. F., Coates, A. S., & Goldhirsch, A. (2009). Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Research and Treatment, 116(3), 491-500. https://doi.org/10.1007/s10549-008-0225-9